Scarica l'app Stockscreener
0.00
100.00%
-90.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$90.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$6.83B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
0.00
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$97.14
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
0.00 | 6.83B | 35.93M | -244.56M | -157.31M | -3.95 |
VRTX
Vertex Pharmaceuticals Inc
|
436.47 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.50 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.00 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.51 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-08-25 | Iniziato | Alliance Global Partners | Buy |
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
MerusFinancial Details - Crunchbase
Merus NV stock (NL0011375928): pipeline momentum and clinical updates keep biotech in focus - AD HOC NEWS
Merus NV stock (NL0011375928): biotech share jumps after solid Q1 data and outlook - AD HOC NEWS
Merus NV stock (NL0011375928): immuno-oncology player in focus after pipeline and data updates - AD HOC NEWS
Oculis Holding Ag Announces Board and Committee Changes - marketscreener.com
FDA Approval for BIZENGRI issued to MERUS N.V. - Quantisnow
TradingKey - TradingKey
Genmab Announces Financial Results for the First Quarter of 2026 - NTB Kommunikasjon
Merus N.V. announces proposed public offering of common shares - MSN
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - MSN
Wells Fargo Downgrades Merus N.V. (MRUS) - MSN
Goldman's 48 potential M&A candidates - MSN
Merus (MRUS) Stifel 2024 Healthcare Conference Summary - Quartr
Merus (MRUS) Investor Update Summary - Quartr
Merus (MRUS) Proxy Filing Summary - Quartr
Merus (MRUS) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Portfolio Update: Will Merus NV benefit from rising consumer demandEarnings Growth Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
GMAB SEC FilingsGenmab 10-K, 10-Q, 8-K Forms - Stock Titan
Swing Trade: Is Merus NV exposed to currency risks2026 Momentum & Breakout Confirmation Trade Signals - baoquankhu1.vn
Trade Report: Is Merus NV on track to beat earnings2026 Short Interest & Daily Momentum Trading Reports - baoquankhu1.vn
Aug Weekly: Is Merus NV being accumulated by smart money2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Merus NVInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Merus NV Stock: Genmab Acquisition Deal at $97 Per Share Reshapes Biotech Investment Landscape for N - AD HOC NEWS
Bank Watch: Is Merus NV on track to beat earningsWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
Bull Run: Can Merus NV reach all time highs this year2026 Buyback Activity & Safe Entry Zone Tips - baoquankhu1.vn
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Stock Recap: Can Merus NV reach all time highs this yearRate Hike & Target Return Focused Stock Picks - baoquankhu1.vn
Merus NV Stock (ISIN: NL0011375928) Gains Momentum on Bispecific Antibody Pipeline Progress - AD HOC NEWS
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race - MSN
Growth Review: Is Merus NV a good ESG investment2026 Setups & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Precision Trading with Merus N.v. (MRUS) Risk Zones - Stock Traders Daily
How Merus N.V. stock reacts to bond yieldsTrade Analysis Report & Low Risk Profit Maximizing Plans - Naître et grandir
Dividend Watch: Is Merus NV being accumulated by smart moneyMarket Sentiment Review & Consistent Profit Trade Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Aug Summary: Is Merus NV a good ESG investment2025 Big Picture & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews
Genmab Publishes 2025 Annual Report - GlobeNewswire
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
What is Merus N.V. s 5 year growth outlookWeekly Stock Summary & AI Enhanced Trading Signals - mfd.ru
Targets Report: Will Merus N.V. stock outperform tech sector in 2025Weekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals - Citeline News & Insights
Is Merus N.V. stock trading near support levelsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Published on: 2026-02-10 12:58:35 - mfd.ru
Can Merus N.V. reach all time highs this year2025 Major Catalysts & Proven Capital Preservation Methods - mfd.ru
Merus N.V. (MRUS) Stock Analysis: Weighing The 7.78% Potential Upside For Investors - DirectorsTalk Interviews
Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Downgrade: Is Merus NV gaining market shareJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Growth Recap: What are Can Fite BioPharma Ltd Depositary Receipts technical support levels - baoquankhu1.vn
Aug Ideas: Is Merus NV a turnaround storyJuly 2025 PreEarnings & AI Enhanced Execution Alerts - baoquankhu1.vn
Fourteen option delistings on January 21st - TipRanks
Merus N.V. (MRUS) Stock Analysis: Biotechnology Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):